Questions and facts regarding denosumab discontinuation among postmenopausal women

Click to increase image sizeClick to decrease image size

Declaration of interests

P Makras has received lecture fees and research grants from Amgen; lecture fees from Glaxo, Lilly, Pfizer, Leo, Genesis, ELPEN, VIANEX, Rafarm, UCB, Takeda. ADA has received lecture fees from Amgen, Eli-Lilly, ELPEN, ITF Hellas, VIANEX. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.